Melanoma Cancer Diagnostics Market, Global Outlook and Forecast 2022-2028

July 2024 | 68 pages | ID: M8B7CB7DDF04EN
Market Monitor Global

Abstracts

Melanoma is a type of skin cancer developing from pigment-containing cells known as melanocytes. Melanoma cancer diagnostics is to diagnose melanoma with biopsy. During a biopsy, all or the part of mole or growth over the skin is removed to test and analyze the sample. Common biopsy procedures used to diagnose melanoma are punch biopsy, incisional biopsy, and excisional biopsy.

This report contains market size and forecasts of Melanoma Cancer Diagnostics in Global, including the following market information:

Global Melanoma Cancer Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Melanoma Cancer Diagnostics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Fluorescent In Situ Hybridization (FISH) Tests Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Melanoma Cancer Diagnostics include AB Sciences, Incyte, Merck, Novartis, Pierre Fabre, Amgen, AstraZeneca, Bristol-Myers Squibb and Daiichi Sankyo. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Melanoma Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Melanoma Cancer Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Melanoma Cancer Diagnostics Market Segment Percentages, by Type, 2021 (%)

• Fluorescent In Situ Hybridization (FISH) Tests
• Comparative Genomic Hybridization (CGH) Tests
• Immunohistochemical (IHC) Tests

Global Melanoma Cancer Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Melanoma Cancer Diagnostics Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Cancer Research Centres
• Others

Global Melanoma Cancer Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Melanoma Cancer Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Melanoma Cancer Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Melanoma Cancer Diagnostics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AB Sciences
• Incyte
• Merck
• Novartis
• Pierre Fabre
• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Daiichi Sankyo

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Melanoma Cancer Diagnostics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Melanoma Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL MELANOMA CANCER DIAGNOSTICS OVERALL MARKET SIZE

2.1 Global Melanoma Cancer Diagnostics Market Size: 2021 VS 2028
2.2 Global Melanoma Cancer Diagnostics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Melanoma Cancer Diagnostics Players in Global Market
3.2 Top Global Melanoma Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Melanoma Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Melanoma Cancer Diagnostics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Melanoma Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Melanoma Cancer Diagnostics Players in Global Market
  3.6.1 List of Global Tier 1 Melanoma Cancer Diagnostics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Melanoma Cancer Diagnostics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Melanoma Cancer Diagnostics Market Size Markets, 2021 & 2028
  4.1.2 Fluorescent In Situ Hybridization (FISH) Tests
  4.1.3 Comparative Genomic Hybridization (CGH) Tests
  4.1.4 Immunohistochemical (IHC) Tests
4.2 By Type - Global Melanoma Cancer Diagnostics Revenue & Forecasts
  4.2.1 By Type - Global Melanoma Cancer Diagnostics Revenue, 2017-2022
  4.2.2 By Type - Global Melanoma Cancer Diagnostics Revenue, 2023-2028
  4.2.3 By Type - Global Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Melanoma Cancer Diagnostics Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Cancer Research Centres
  5.1.5 Others
5.2 By Application - Global Melanoma Cancer Diagnostics Revenue & Forecasts
  5.2.1 By Application - Global Melanoma Cancer Diagnostics Revenue, 2017-2022
  5.2.2 By Application - Global Melanoma Cancer Diagnostics Revenue, 2023-2028
  5.2.3 By Application - Global Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Melanoma Cancer Diagnostics Market Size, 2021 & 2028
6.2 By Region - Global Melanoma Cancer Diagnostics Revenue & Forecasts
  6.2.1 By Region - Global Melanoma Cancer Diagnostics Revenue, 2017-2022
  6.2.2 By Region - Global Melanoma Cancer Diagnostics Revenue, 2023-2028
  6.2.3 By Region - Global Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Melanoma Cancer Diagnostics Revenue, 2017-2028
  6.3.2 US Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.3.3 Canada Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.3.4 Mexico Melanoma Cancer Diagnostics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Melanoma Cancer Diagnostics Revenue, 2017-2028
  6.4.2 Germany Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.4.3 France Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.4.4 U.K. Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.4.5 Italy Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.4.6 Russia Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.4.7 Nordic Countries Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.4.8 Benelux Melanoma Cancer Diagnostics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Melanoma Cancer Diagnostics Revenue, 2017-2028
  6.5.2 China Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.5.3 Japan Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.5.4 South Korea Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.5.5 Southeast Asia Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.5.6 India Melanoma Cancer Diagnostics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Melanoma Cancer Diagnostics Revenue, 2017-2028
  6.6.2 Brazil Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.6.3 Argentina Melanoma Cancer Diagnostics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Melanoma Cancer Diagnostics Revenue, 2017-2028
  6.7.2 Turkey Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.7.3 Israel Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.7.4 Saudi Arabia Melanoma Cancer Diagnostics Market Size, 2017-2028
  6.7.5 UAE Melanoma Cancer Diagnostics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AB Sciences
  7.1.1 AB Sciences Corporate Summary
  7.1.2 AB Sciences Business Overview
  7.1.3 AB Sciences Melanoma Cancer Diagnostics Major Product Offerings
  7.1.4 AB Sciences Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.1.5 AB Sciences Key News
7.2 Incyte
  7.2.1 Incyte Corporate Summary
  7.2.2 Incyte Business Overview
  7.2.3 Incyte Melanoma Cancer Diagnostics Major Product Offerings
  7.2.4 Incyte Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.2.5 Incyte Key News
7.3 Merck
  7.3.1 Merck Corporate Summary
  7.3.2 Merck Business Overview
  7.3.3 Merck Melanoma Cancer Diagnostics Major Product Offerings
  7.3.4 Merck Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.3.5 Merck Key News
7.4 Novartis
  7.4.1 Novartis Corporate Summary
  7.4.2 Novartis Business Overview
  7.4.3 Novartis Melanoma Cancer Diagnostics Major Product Offerings
  7.4.4 Novartis Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.4.5 Novartis Key News
7.5 Pierre Fabre
  7.5.1 Pierre Fabre Corporate Summary
  7.5.2 Pierre Fabre Business Overview
  7.5.3 Pierre Fabre Melanoma Cancer Diagnostics Major Product Offerings
  7.5.4 Pierre Fabre Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.5.5 Pierre Fabre Key News
7.6 Amgen
  7.6.1 Amgen Corporate Summary
  7.6.2 Amgen Business Overview
  7.6.3 Amgen Melanoma Cancer Diagnostics Major Product Offerings
  7.6.4 Amgen Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.6.5 Amgen Key News
7.7 AstraZeneca
  7.7.1 AstraZeneca Corporate Summary
  7.7.2 AstraZeneca Business Overview
  7.7.3 AstraZeneca Melanoma Cancer Diagnostics Major Product Offerings
  7.7.4 AstraZeneca Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.7.5 AstraZeneca Key News
7.8 Bristol-Myers Squibb
  7.8.1 Bristol-Myers Squibb Corporate Summary
  7.8.2 Bristol-Myers Squibb Business Overview
  7.8.3 Bristol-Myers Squibb Melanoma Cancer Diagnostics Major Product Offerings
  7.8.4 Bristol-Myers Squibb Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.8.5 Bristol-Myers Squibb Key News
7.9 Daiichi Sankyo
  7.9.1 Daiichi Sankyo Corporate Summary
  7.9.2 Daiichi Sankyo Business Overview
  7.9.3 Daiichi Sankyo Melanoma Cancer Diagnostics Major Product Offerings
  7.9.4 Daiichi Sankyo Melanoma Cancer Diagnostics Revenue in Global Market (2017-2022)
  7.9.5 Daiichi Sankyo Key News

8 CONCLUSION


9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Melanoma Cancer Diagnostics Market Opportunities & Trends in Global Market
Table 2. Melanoma Cancer Diagnostics Market Drivers in Global Market
Table 3. Melanoma Cancer Diagnostics Market Restraints in Global Market
Table 4. Key Players of Melanoma Cancer Diagnostics in Global Market
Table 5. Top Melanoma Cancer Diagnostics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Melanoma Cancer Diagnostics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Melanoma Cancer Diagnostics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Melanoma Cancer Diagnostics Product Type
Table 9. List of Global Tier 1 Melanoma Cancer Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Melanoma Cancer Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Melanoma Cancer Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Melanoma Cancer Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Melanoma Cancer Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Melanoma Cancer Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Melanoma Cancer Diagnostics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Melanoma Cancer Diagnostics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2023-2028
Table 30. AB Sciences Corporate Summary
Table 31. AB Sciences Melanoma Cancer Diagnostics Product Offerings
Table 32. AB Sciences Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)
Table 33. Incyte Corporate Summary
Table 34. Incyte Melanoma Cancer Diagnostics Product Offerings
Table 35. Incyte Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)
Table 36. Merck Corporate Summary
Table 37. Merck Melanoma Cancer Diagnostics Product Offerings
Table 38. Merck Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)
Table 39. Novartis Corporate Summary
Table 40. Novartis Melanoma Cancer Diagnostics Product Offerings
Table 41. Novartis Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)
Table 42. Pierre Fabre Corporate Summary
Table 43. Pierre Fabre Melanoma Cancer Diagnostics Product Offerings
Table 44. Pierre Fabre Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)
Table 45. Amgen Corporate Summary
Table 46. Amgen Melanoma Cancer Diagnostics Product Offerings
Table 47. Amgen Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)
Table 48. AstraZeneca Corporate Summary
Table 49. AstraZeneca Melanoma Cancer Diagnostics Product Offerings
Table 50. AstraZeneca Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)
Table 51. Bristol-Myers Squibb Corporate Summary
Table 52. Bristol-Myers Squibb Melanoma Cancer Diagnostics Product Offerings
Table 53. Bristol-Myers Squibb Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)
Table 54. Daiichi Sankyo Corporate Summary
Table 55. Daiichi Sankyo Melanoma Cancer Diagnostics Product Offerings
Table 56. Daiichi Sankyo Melanoma Cancer Diagnostics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Melanoma Cancer Diagnostics Segment by Type in 2021
Figure 2. Melanoma Cancer Diagnostics Segment by Application in 2021
Figure 3. Global Melanoma Cancer Diagnostics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Melanoma Cancer Diagnostics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Melanoma Cancer Diagnostics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Melanoma Cancer Diagnostics Revenue in 2021
Figure 8. By Type - Global Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
Figure 12. US Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
Figure 16. Germany Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 17. France Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
Figure 24. China Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 28. India Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
Figure 30. Brazil Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Melanoma Cancer Diagnostics Revenue Market Share, 2017-2028
Figure 33. Turkey Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Melanoma Cancer Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 37. AB Sciences Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Incyte Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Merck Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pierre Fabre Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Amgen Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AstraZeneca Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Bristol-Myers Squibb Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Daiichi Sankyo Melanoma Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)